KR101961508B1 - Tdp-43 특이적 결합 분자 - Google Patents

Tdp-43 특이적 결합 분자 Download PDF

Info

Publication number
KR101961508B1
KR101961508B1 KR1020147014139A KR20147014139A KR101961508B1 KR 101961508 B1 KR101961508 B1 KR 101961508B1 KR 1020147014139 A KR1020147014139 A KR 1020147014139A KR 20147014139 A KR20147014139 A KR 20147014139A KR 101961508 B1 KR101961508 B1 KR 101961508B1
Authority
KR
South Korea
Prior art keywords
seq
tdp
antibody
disease
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147014139A
Other languages
English (en)
Korean (ko)
Other versions
KR20140100480A (ko
Inventor
로거 니치
크리슈토프 호크
몬트라시오 마리아 그라치아 바렌코
파비오 몬트라시오
얀 그림
장-뤽 베리스빌
폴 웨인랩
자나키 쿠마라스와미
오마르 퀸테로-몬존
Original Assignee
바이오겐 인터내셔널 뉴로사이언스 게엠베하
유니버시티 오브 취리히
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오겐 인터내셔널 뉴로사이언스 게엠베하, 유니버시티 오브 취리히 filed Critical 바이오겐 인터내셔널 뉴로사이언스 게엠베하
Publication of KR20140100480A publication Critical patent/KR20140100480A/ko
Application granted granted Critical
Publication of KR101961508B1 publication Critical patent/KR101961508B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • Psychology (AREA)
KR1020147014139A 2011-10-28 2012-10-26 Tdp-43 특이적 결합 분자 Expired - Fee Related KR101961508B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553113P 2011-10-28 2011-10-28
US61/553,113 2011-10-28
PCT/IB2012/002905 WO2013061163A2 (en) 2011-10-28 2012-10-26 Tdp-43 specific binding molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187035073A Division KR102032080B1 (ko) 2011-10-28 2012-10-26 Tdp-43 특이적 결합 분자

Publications (2)

Publication Number Publication Date
KR20140100480A KR20140100480A (ko) 2014-08-14
KR101961508B1 true KR101961508B1 (ko) 2019-03-25

Family

ID=47720540

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147014139A Expired - Fee Related KR101961508B1 (ko) 2011-10-28 2012-10-26 Tdp-43 특이적 결합 분자
KR1020187035073A Expired - Fee Related KR102032080B1 (ko) 2011-10-28 2012-10-26 Tdp-43 특이적 결합 분자

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187035073A Expired - Fee Related KR102032080B1 (ko) 2011-10-28 2012-10-26 Tdp-43 특이적 결합 분자

Country Status (18)

Country Link
US (3) US9587014B2 (enExample)
EP (2) EP2771359B1 (enExample)
JP (3) JP6240611B2 (enExample)
KR (2) KR101961508B1 (enExample)
CN (1) CN104159918B (enExample)
AU (1) AU2012327211C9 (enExample)
BR (1) BR112014010161B1 (enExample)
CA (2) CA2853412C (enExample)
CL (1) CL2014001074A1 (enExample)
EA (1) EA032003B1 (enExample)
ES (1) ES2883212T3 (enExample)
IL (2) IL232219B (enExample)
MX (2) MX357678B (enExample)
MY (1) MY167795A (enExample)
PH (1) PH12014500940A1 (enExample)
SG (1) SG11201401735WA (enExample)
WO (1) WO2013061163A2 (enExample)
ZA (1) ZA201403680B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
KR101961508B1 (ko) 2011-10-28 2019-03-25 바이오겐 인터내셔널 뉴로사이언스 게엠베하 Tdp-43 특이적 결합 분자
US11401321B2 (en) 2013-06-11 2022-08-02 Paul Scherrer Institut Method for determining mutateable ligand-GPCR binding at single amino acid resolution and pairs of mutated ligand and GPCR
WO2015117088A2 (en) 2014-01-31 2015-08-06 Arizona Board Of Regents On Behalf Of Arizona State University Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
AU2015295441B2 (en) 2014-07-29 2020-05-14 Neurimmune Holding Ag Human-derived anti-huntingtin (HTT) antibodies and uses thereof
CN104497121A (zh) * 2014-08-29 2015-04-08 苏州顺升桥生物科技有限公司 淀粉样蛋白tdp-43及其用途
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
TWI592423B (zh) * 2014-10-03 2017-07-21 中央研究院 可辨識致病性ｔｄｐ－４３之抗體及其用途
EP3200825A4 (en) 2014-10-03 2018-03-21 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2016196324A1 (en) 2015-05-29 2016-12-08 University Of Floridia Research Foundation, Inc. Methods for diagnosing huntington's disease
WO2017111166A1 (ja) * 2015-12-25 2017-06-29 国立大学法人東京農工大学 Ｔｄｐ－４３細胞内存在量関連疾患治療剤
PL3430397T3 (pl) 2016-03-14 2022-04-04 Biogen International Neuroscience Gmbh Oznaczenie fagocytozy zależnej od przeciwciał do wiarygodnych pomiarów wychwytu zagregowanych białek
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
MA45715A (fr) 2016-07-25 2019-05-29 Biogen Ma Inc Anticorps anti-hspa5 (grp78) et leurs utilisations
WO2018112362A1 (en) 2016-12-16 2018-06-21 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
AU2018236218B2 (en) * 2017-03-14 2025-03-06 Bristol-Myers Squibb Company Antibodies binding to vista at acidic pH
JP7526455B2 (ja) 2017-04-17 2024-08-01 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． ＰＫＲおよびｅＩＦ２Ａ－Ｐ経路によるＲＡＮタンパク質翻訳の調節
WO2018218352A1 (en) * 2017-05-30 2018-12-06 The University Of British Columbia Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto
DK3672631T5 (da) 2017-08-22 2024-08-26 Biogen Ma Inc Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
CA3075908A1 (en) 2017-09-25 2019-03-28 University Of Florida Research Foundation, Incorporated Immunoassays for detection of ran proteins
EP3724232B1 (en) 2017-12-14 2024-12-04 The University of Ottawa Exosome packaging and targeted autophagy
US11246857B2 (en) * 2017-12-14 2022-02-15 The Johns Hopkins University Anti-fungal inhibitors
SG11202006348VA (en) * 2018-01-05 2020-07-29 Ac Immune Sa Misfolded tdp-43 binding molecules
CN112236523A (zh) * 2018-03-16 2021-01-15 国立大学法人滋贺医科大学 降解和去除异常tdp-43的抗体片段
JP7510879B2 (ja) 2018-03-21 2024-07-04 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体
TW202019398A (zh) * 2018-06-28 2020-06-01 張翔毓 用於治療或預防構形疾病之方法及藥物篩選方法
SG11202100102VA (en) 2018-07-11 2021-02-25 Five Prime Therapeutics Inc Antibodies binding to vista at acidic ph
MA54070A (fr) 2018-10-29 2021-09-08 Biogen Ma Inc Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique
EP3894433A4 (en) * 2018-12-14 2022-08-31 The University of British Columbia Antibodies to misfolded tdp-43 and methods of use
US20220315648A1 (en) * 2019-05-23 2022-10-06 Ac Immune Sa Anti-TDP-43 Binding Molecules and Uses Thereof
CN114514240B (zh) * 2019-08-12 2024-11-19 麦考瑞大学 用于治疗的组合物和方法
JP7620988B2 (ja) * 2019-09-20 2025-01-24 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 血清および組織ライセートからのｒａｎタンパク質に対する抗体の検出
GB202004863D0 (en) * 2020-04-02 2020-05-20 Univ Oxford Innovation Ltd Method
WO2021222168A2 (en) 2020-04-28 2021-11-04 Sola Biosciences Llc Compositions and methods for the treatment of tdp-43 proteinopathies
CN115803054A (zh) * 2020-04-29 2023-03-14 英属哥伦比亚大学 针对错误折叠的tdp-43的单链抗体和胞内抗体及其使用方法
WO2022010761A1 (en) * 2020-07-06 2022-01-13 The Board Of Regents Of The University Of Texas System Tdp-43 biosensor cell lines
TW202221026A (zh) 2020-08-14 2022-06-01 瑞士商Ａｃ 免疫有限公司 人源化抗ｔｄｐ－４３結合分子及其用途
CA3203308A1 (en) 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
WO2022164288A1 (ko) 2021-01-29 2022-08-04 한국과학기술원 비염증성 식세포작용 유도 활성을 갖는 융합분자
CN112920264B (zh) * 2021-02-08 2022-07-05 武汉大学 Tdp-43蛋白的o-糖基化突变体及其应用
JP6961278B1 (ja) * 2021-03-10 2021-11-05 国立研究開発法人量子科学技術研究開発機構 生体試料中のｔｄｐ−４３を測定する方法及び装置
AU2022282368A1 (en) * 2021-05-27 2023-11-30 Mayo Foundation For Medical Education And Research Methods and materials for treating proteinopathies
CA3231484A1 (en) * 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
EP4479426A1 (en) 2022-02-16 2024-12-25 AC Immune SA Humanized anti-tdp-43 binding molecules and uses thereof
JP2025513799A (ja) * 2022-04-08 2025-04-30 エイシー イミューン ソシエテ アノニム 抗ｔｄｐ－４３結合分子
WO2023205579A1 (en) * 2022-04-18 2023-10-26 The Regents Of The University Of California Compositions and methods for disrupting pathological aggregates
WO2023204313A1 (ja) 2022-04-22 2023-10-26 国立大学法人新潟大学 Ｔｄｐ－４３の凝集抑制剤及び医薬組成物
CN120917043A (zh) 2023-03-08 2025-11-07 Ac免疫有限公司 抗tdp-43结合分子及其用途
WO2024263701A1 (en) * 2023-06-20 2024-12-26 The Trustees Of Dartmouth College Chimeric antigen receptors (cars) targeting tdp43, tregs expressing said cars, and use thereof for the treatment of als, ftd and ad
KR102859015B1 (ko) * 2023-07-20 2025-09-12 충북대학교 산학협력단 ｃ­Ａｂｌ에 의한 ＴＤＰ­４３의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법
CN116875738A (zh) * 2023-07-24 2023-10-13 山东省农业科学院畜牧兽医研究所 一种鉴定牛tdp-43基因启动子活性区域的方法
AR133828A1 (es) * 2023-09-15 2025-11-05 Prothena Biosciences Ltd Anticuerpos anti-tdp-43 y sus usos
WO2025186332A1 (en) 2024-03-05 2025-09-12 Ac Immune Sa Vectorized anti-tdp-43 antibodies
WO2026013218A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Anti-tdp-43 vectors, binding molecules and uses thereof
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008529A1 (ja) * 2007-07-06 2009-01-15 Tokyo Metropolitan Organization For Medical Research Ｔｄｐ－４３凝集物に特異的に結合する抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688511A (en) 1991-11-05 1997-11-18 Board Of Regents, The University Of Texas System Cellular protein TDP-43 and regulation of HIV-1 gene expression
CA2253633A1 (en) 1997-12-03 1999-06-03 Boehringer Mannheim Corporation Complex specific antibodies, method of preparation and uses thereof
US8354236B2 (en) * 2006-09-29 2013-01-15 The Trustees Of The University Of Pennsylvania Detection of neurodegenerative disease
PL2426143T3 (pl) 2007-01-05 2017-12-29 University Of Zurich Sposób zapewniania specyficznych wobec choroby cząsteczek wiążących i celów
WO2008151055A1 (en) 2007-06-01 2008-12-11 Mayo Foundation For Medical Education And Research Diagnosing neurodegenerative diseases
WO2009099941A2 (en) * 2008-02-01 2009-08-13 Washington University In St. Louis Sequences associated with tdp-43 proteinopathies and methods of using the same
DK2370466T3 (en) 2008-12-19 2015-08-03 Univ Zuerich Humane anti-alpha-synuclein-autoantistoffer
CN101634656A (zh) * 2009-08-21 2010-01-27 武汉三鹰生物技术有限公司 人tdp-43的单抗包被酶标板的制法及elisa检测试剂盒
KR101961508B1 (ko) 2011-10-28 2019-03-25 바이오겐 인터내셔널 뉴로사이언스 게엠베하 Tdp-43 특이적 결합 분자

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008529A1 (ja) * 2007-07-06 2009-01-15 Tokyo Metropolitan Organization For Medical Research Ｔｄｐ－４３凝集物に特異的に結合する抗体

Also Published As

Publication number Publication date
US20170152308A1 (en) 2017-06-01
ES2883212T3 (es) 2021-12-07
EA032003B1 (ru) 2019-03-29
CA3112082A1 (en) 2013-05-02
JP6652609B2 (ja) 2020-02-26
JP2017205118A (ja) 2017-11-24
BR112014010161B1 (pt) 2022-02-08
NZ624871A (en) 2016-06-24
AU2012327211B2 (en) 2016-03-10
IL232219B (en) 2019-11-28
JP6240611B2 (ja) 2017-11-29
MX2018008680A (es) 2023-04-18
JP2019022500A (ja) 2019-02-14
MX2014005048A (es) 2014-11-10
US9587014B2 (en) 2017-03-07
CN104159918B (zh) 2019-09-13
AU2012327211A1 (en) 2013-05-23
ZA201403680B (en) 2020-05-27
MY167795A (en) 2018-09-26
IL232219A0 (en) 2014-06-30
AU2012327211C1 (en) 2016-09-15
KR102032080B1 (ko) 2019-10-15
EP3964524A1 (en) 2022-03-09
JP6417451B2 (ja) 2018-11-07
EA201490825A1 (ru) 2015-01-30
SG11201401735WA (en) 2014-05-29
WO2013061163A3 (en) 2014-03-06
KR20140100480A (ko) 2014-08-14
EA201490825A8 (ru) 2016-09-30
HK1201846A1 (en) 2015-09-11
BR112014010161A2 (pt) 2018-09-25
MX357678B (es) 2018-07-19
AU2012327211C9 (en) 2016-11-17
CA2853412A1 (en) 2013-05-02
CA2853412C (en) 2021-05-04
JP2015505665A (ja) 2015-02-26
CL2014001074A1 (es) 2015-01-09
KR20180132977A (ko) 2018-12-12
US20140255304A1 (en) 2014-09-11
US10259866B2 (en) 2019-04-16
IL270223B (en) 2021-05-31
PH12014500940A1 (en) 2019-06-26
CN104159918A (zh) 2014-11-19
EP2771359A2 (en) 2014-09-03
US20200017577A1 (en) 2020-01-16
EP2771359B1 (en) 2021-05-19
US11091540B2 (en) 2021-08-17
WO2013061163A2 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
KR101961508B1 (ko) Tdp-43 특이적 결합 분자
US12234281B2 (en) Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
KR102234324B1 (ko) 인간 항-타우 항체
US10703808B2 (en) Human anti-alpha-synuclein antibodies
KR101976887B1 (ko) 항-알파 시누클레인 결합 분자
KR102594327B1 (ko) 인간-유래의 항-디펩티드 반복체(dpr) 항체
CN107074937B (zh) 人源抗亨廷顿蛋白(htt)抗体及其用途
EA031698B1 (ru) Человеческие анти-тау антитела
HK40069392A (en) Tdp-43 specific binding molecules
KR102924207B1 (ko) 트랜스티레틴(ttr) 아밀로이드증의 항체-기반의 치료 및 이를 위한 인간-유래의 항체
HK1201846B (en) Tdp-43 specific binding molecules

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A107 Divisional application of patent
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250320

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250320

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250320